For the pharmacotherapy of choreatic hyperkinesia, D2/D3-dopamine receptor antagonists (e.g., tiapride) and inhibitors of vesicular monoamine Transporter 2 (VMAT2; e.g., tetrabenazine) are available. This evidence concerns the gene SLC18A2 and Hyperkinetic movements.